Affimed (AFMD) Granted FDA Fast Track Designation for AFM13 in Combination with AlloNK streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AFM13 in combination with AlloNK® (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the treatment in
Immuno-oncology company Affimed N.V. (AFMD) announced that the FDA has granted fast track designation to the combination of its innate cell engager (ICE) AFM13 with AlloNK for the potential treatment of relapsed/refractory (r/r) Hodgkin lymphoma (HL).